Organized by the global Preclinical Data Forum, the meeting is aimed to start a discussion about developing specific quality guidelines and standards for in vitro research. One key question to be addressed at the meeting is whether quality recommendations, which are increasingly commonly acknowledged and followed in in vivo research, like blinding and randomization, should and can also be applied for in vitro studies and which characteristics/situations prevent the implementation of such measures.
Participants will be from academia as well as biotech and pharma companies.
We will update you with more details soon…